Post the big ticket acquisition of Arysta LifeScience last year, UPL has reported a subdued set of Q4 results.
While the operating performance (excluding Arysta remained healthy), the combined numbers remained impacted.
Sakshi Batra does a 3 Point Analysis of the earnings fine print and shares an outlook on the company.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
